Caris Life Sciences Inc (CAI) USD0.001

Sell:$22.00Buy:$22.01Price increased$0.75 (3.53%)

NASDAQ:Price increased2.18%
Market closed |
Prices delayed by at least 15 minutes
Sell:$22.00
Buy:$22.01
Change:Price increased$0.75 (3.53%)
Market closed |
Prices delayed by at least 15 minutes
Sell:$22.00
Buy:$22.01
Change:Price increased$0.75 (3.53%)
Market closed |
Prices delayed by at least 15 minutes

Company Information

About this company

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Key people

David Dean Halbert
Chairman of the Board, Chief Executive Officer, Founder
David Spetzler
President
Brian J. Brille
Vice Chairman of the Board, Executive Vice President
Jonathan Knowles
Vice Chairman of the Board
George H. Poste
Vice Chairman of the Board
Luke Power
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
J. Russel Denton
Senior Vice President, General Counsel, Secretary
Narendra Chokshi
Senior Vice President - Corporate Development
Peter M. Castleman
Lead Independent Director
Jon S. Halbert
Director
Nathan Burns
Independent Director
David Fredrickson
Independent Director
Joseph E. Gilliam
Independent Director
Click to see more

Key facts

  • Shares in issue
    283.77m
  • EPIC
    CAI
  • ISIN
    US1421521071
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $6.16bn
  • Employees
    -
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.